- Home
- ATXS vs NDMO Comparison
ATXS vs NDMO Comparison
Compare ATXS & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATXS
- NDMO
- Stock Information
- Founded
- ATXS 2008
- NDMO 2019
- Country
- ATXS United States
- NDMO United States
- Employees
- ATXS N/A
- NDMO N/A
- Industry
- ATXS Biotechnology: Pharmaceutical Preparations
- NDMO Trusts Except Educational Religious and Charitable
- Sector
- ATXS Health Care
- NDMO Finance
- Exchange
- ATXS Nasdaq
- NDMO Nasdaq
- Market Cap
- ATXS 676.1M
- NDMO 633.1M
- IPO Year
- ATXS 2015
- NDMO N/A
- Fundamental
- Price
- ATXS $12.50
- NDMO $10.43
- Analyst Decision
- ATXS Hold
- NDMO
- Analyst Count
- ATXS 6
- NDMO 0
- Target Price
- ATXS $24.33
- NDMO N/A
- AVG Volume (30 Days)
- ATXS 936.9K
- NDMO 218.6K
- Earning Date
- ATXS 11-12-2025
- NDMO 01-01-0001
- Dividend Yield
- ATXS N/A
- NDMO 6.75%
- EPS Growth
- ATXS N/A
- NDMO N/A
- EPS
- ATXS N/A
- NDMO N/A
- Revenue
- ATXS $706,000.00
- NDMO N/A
- Revenue This Year
- ATXS N/A
- NDMO N/A
- Revenue Next Year
- ATXS N/A
- NDMO N/A
- P/E Ratio
- ATXS N/A
- NDMO N/A
- Revenue Growth
- ATXS N/A
- NDMO N/A
- 52 Week Low
- ATXS $3.56
- NDMO $8.99
- 52 Week High
- ATXS $12.72
- NDMO $11.24
- Technical
- Relative Strength Index (RSI)
- ATXS 67.29
- NDMO 41.75
- Support Level
- ATXS $12.31
- NDMO $10.25
- Resistance Level
- ATXS $12.62
- NDMO $10.68
- Average True Range (ATR)
- ATXS 0.23
- NDMO 0.17
- MACD
- ATXS -0.17
- NDMO -0.03
- Stochastic Oscillator
- ATXS 72.73
- NDMO 33.33
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.